Tennessee 2025-2026 Regular Session

Tennessee Senate Bill SB2020

Caption

AN ACT to amend Tennessee Code Annotated, Title 56, Chapter 7, relative to health insurance practices.

Summary

SB2020 makes broad changes to Tennessee’s health insurance laws governing prior authorization, claim payment, downcoding, and the use of artificial intelligence in claims processing. The bill defines AI for purposes of medical claims administration and prohibits a health carrier from denying, delaying, or modifying care solely because of an AI or automated software determination; adverse medical-necessity decisions must be made by a licensed physician after reviewing the treating provider’s recommendation and the patient’s clinical history. It also expands protections for certain services by limiting or eliminating prior authorization for a list of drugs and treatments, including opioid use disorder medication, outpatient mental health and substance use disorder treatment, preventive services, pediatric hospice, neonatal abstinence treatment, HIV antiretrovirals, gynecological procedures, and certain cancer therapies, while also extending prior authorization approvals for chronic-condition treatment and creating a 90-day continuity period when patients change carriers. The bill also revises prompt-payment rules for health insurance claims. It clarifies when a claim is considered “submitted,” shortens payment timelines for electronic claims, requires insurers to provide specific reasons and documentation requests when a claim is not clean, and requires acknowledgment of additional documentation within 10 business days. In addition, it adds new audit authority for the commissioner of commerce and insurance to review carrier compliance with prompt-payment and prior-authorization requirements at least every three years beginning in 2027, with authority to order corrective action and civil penalties and to charge audit costs to carriers. A major portion of the bill addresses reimbursement practices and provider payment methods. It requires health carrier contracts and reimbursement policies to account for a patient’s medical complexity and comorbidities, and it requires reimbursement for additional clinically appropriate services, procedures, or devices furnished during authorized or medically indicated treatment. It also regulates electronic funds transfer and virtual credit card payments by requiring notice of fees and payment options and prohibiting transmission fees unless the provider consents. The bill further bars prior authorization for services paid through certain value-based contracts that tie reimbursement to quality, efficiency, outcomes, and risk-sharing. The bill’s most detailed new section creates a separate framework prohibiting improper downcoding of claims. It bars health insurance entities from downcoding unless a licensed physician or similarly qualified professional makes the decision after documented clinical review, and it requires detailed remittance notices identifying the reason for the downcode, the applicable codes, the original and revised payment amounts, and the reviewer’s credentials. Providers are given a 30-day appeal process, the ability to batch similar appeals, and the option to seek court relief for arbitrary or discriminatory downcoding. Enforcement powers include civil penalties, a 25% penalty on unpaid downcoded claims, and voiding of any contract terms that attempt to waive these protections. Overall, the bill appears aimed at strengthening provider protections, reducing administrative barriers to care, and limiting insurer reliance on automated or opaque claims-management practices. The general sentiment reflected in the bill text is strongly pro-provider and pro-patient access, especially for chronic illness, behavioral health, cancer care, and other high-need services. The main points of contention are likely to be the restrictions on insurer utilization review, the limits on AI-driven claims decisions, the mandatory payment and audit requirements, and the potential compliance and cost burdens on health carriers and utilization review organizations.

Impact

SB2020 would amend multiple provisions of Tennessee Code Annotated Title 56, Chapter 7, creating new statutory limits on prior authorization, claim downcoding, prompt payment, reimbursement practices, and automated claims review. It would add new definitions and enforcement mechanisms, require new carrier disclosures and appeals processes, and expand the authority of the commissioner of commerce and insurance to audit carriers, impose corrective action, and assess penalties. The bill directly affects health carriers, utilization review organizations, healthcare providers, and insured enrollees, and it would apply to many contracts and policies issued, amended, renewed, or delivered on or after the bill’s effective dates.

Sentiment

The bill text reflects a clear policy direction favoring patients and healthcare providers over insurer utilization controls. Although no committee transcripts or recorded votes are available, the structure and findings of the bill suggest concern about insurer practices such as prior authorization delays, AI-based denials, downcoding, and payment friction. The overall tone is reform-oriented and protective of access to care, with an emphasis on transparency, clinical review, and timely reimbursement.

Contention

The most likely areas of dispute are the bill’s restrictions on insurer discretion and its operational and financial impact on carriers. Insurers may object to the prohibition on AI-only adverse determinations, the broad prior-authorization exemptions, the mandatory reimbursement rules for additional services during authorized care, and the detailed downcoding appeal and penalty provisions. Providers and patient advocates are likely to support these provisions, especially those affecting chronic conditions, behavioral health, cancer treatment, and complex patients. The bill also creates potential contention over enforcement costs, audit frequency, and whether the new standards could increase premiums or administrative burden.

Companion Bills

No companion bills found.

Previously Filed As

TN SB1261

AN ACT to amend Tennessee Code Annotated, Title 8, Chapter 27; Title 56 and Title 71, relative to health insurance.

TN HB1382

AN ACT to amend Tennessee Code Annotated, Title 8, Chapter 27; Title 56 and Title 71, relative to health insurance.

TN SB2550

AN ACT to amend Tennessee Code Annotated, Title 56, Chapter 7, relative to health insurance practices.

TN HB2579

AN ACT to amend Tennessee Code Annotated, Title 56, Chapter 7, relative to health insurance practices.

TN HB1866

AN ACT to amend Tennessee Code Annotated, Title 8, Chapter 27; Title 56 and Title 71, relative to health insurance.

TN SB2010

AN ACT to amend Tennessee Code Annotated, Title 8, Chapter 27; Title 56 and Title 71, relative to health insurance.

TN SB2155

AN ACT to amend Tennessee Code Annotated, Title 4; Title 8; Title 56 and Title 71, relative to insurance.

TN HB2619

AN ACT to amend Tennessee Code Annotated, Title 4; Title 8; Title 56 and Title 71, relative to insurance.

TN HB0019

AN ACT to amend Tennessee Code Annotated, Title 8, Chapter 27 and Title 56, Chapter 7, Part 6, relative to covered persons insured under state healthcare plans.

TN SB2036

AN ACT to amend Tennessee Code Annotated, Title 8 and Title 56, relative to health insurance.

Similar Bills

NJ A4190

Codifies certain regulatory provisions regarding controlled dangerous substances and prescription monitoring.

NJ S2374

Prohibits pre-approval or precertification of cancer treatments, tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans.

NJ A289

Requires health care practitioners prescribing opioid medications to limit amount of prescribed medication to seven-day supply, except in certain circumstances.

IL HB3472

OPIOID PATIENTS RIGHT TO KNOW

OK SB1642

Controlled dangerous substances; authorizing divided quantities for certain acute pain opioid prescriptions. Effective date.

NJ A1821

Prohibits health insurance carriers from denying coverage of nonopioid prescription drugs in favor of opioid prescription drugs.

TX SB883

Relating to patient access to prescription drugs for off-label use for COVID-19 treatment.

MS HB956

Opioid drugs; prescriber shall discuss with patient before prescribing, the risks of the drugs and available alternatives.